Oncolytic Viruses Armed with Potent T-cell Stimulators
DNAtrix is developing a pipeline of oncolytic viruses that are armed with powerful T-cell stimulators, designed to unleash robust immune responses against tumors.
The Armed DNX viruses capitalize on the effectiveness of the human immune system by combining a replication-competent oncolytic virus, utilizing the backbone of DNX technology, with potent immune modulators. A pipeline of Armed DNX oncolytic immunotherapies is being developed by making a third genetic modification to the viral genome, encoding powerful T-cell stimulators. Each drug has unique characteristics based on the T-cell modulator utilized, which are exploited to tailor the therapy to specific applications for the treatment of cancer.
Additional Armed DNX viruses are being engineered and evaluated for effectiveness against various cancers.